typhim vi injektionsvæske, opløsning
sanofi pasteur europe - salmonella typhi ty2 vi kapselpolysaccharid - injektionsvæske, opløsning
zofran konserveret 2 mg/ml injektionsvæske, opløsning
novartis healthcare a/s - ondansetron - injektionsvæske, opløsning - 2 mg/ml
typhim vi injektionsvæske, opløsning
orifarm a/s - salmonella typhi ty2 vi kapselpolysaccharid - injektionsvæske, opløsning
typhim vi injektionsvæske, opløsning
paranova danmark a/s - salmonella typhi ty2 vi kapselpolysaccharid - injektionsvæske, opløsning
augermid 2,5 mg tabletter
morningside healthcare (malta) limited - midodrinhydrochlorid - tabletter - 2,5 mg
apretude
viiv healthcare b.v. - cabotegravir - hiv infektioner - antivirale midler til systemisk anvendelse - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4. 2, 4. 4 og 5.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatiske neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
xenetix 250 mg iod/ml injektionsvæske, opløsning
guerbet - iobitridol - injektionsvæske, opløsning - 250 mg iod/ml